Insights from 2023 ASH Annual Meeting


 

CLL/SLL Treatment With Post-cBTKi Pirtobrutinib: 30 Months Follow-Up & Subgroup Analysis With/Without Prior BCL2i From the Ph1/2 BRUIN Study

398 views
December 19, 2023
Comments 0
Login to view comments. Click here to Login